Verdad Advisers’s Terns Pharmaceuticals TERN Stock Holding History

Verdad Advisers’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,301	Closed	-$701K	–	271
2026 Q1	$701K	Buy	+13,301	New	+$546K	0.79%	38

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Verdad Advisers's TERN Position: Q2 2026 in Review

Verdad Advisers sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 13,301 shares — an estimated $701K sold.

Verdad Advisers first reported a position in TERN in Q1 2026 and held it in 1 quarter. The position peaked at $701K in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Verdad Advisers reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Verdad Advisers sold 13,301 Terns Pharmaceuticals shares in Q2 2026, an estimated $701K.
Verdad Advisers first reported a position in Terns Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Verdad Advisers's Terns Pharmaceuticals position peaked at $701K in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.